|
1
|
Sarduy MR, García I, Coca MA, Perera A, Torres LA, Valenzuela CM, Baladrón I, Solares M, Reyes V, Hernández I, Perera Y, Martínez YM, Molina L, González YM, Ancízar JA, Prats A, González L, Casacó CA, Acevedo BE, López-Saura PA, Alonso DF, Gómez R, Perea-Rodríguez SE. Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer. Br J Cancer 2015; 112:1636-43. [PMID: 25880012 PMCID: PMC4430720 DOI: 10.1038/bjc.2015.137] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2015] [Revised: 03/17/2015] [Accepted: 03/19/2015] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND We conducted a phase 1 trial in patients with locally advanced cervical cancer by injecting 0.5 ml of the CK2-antagonist CIGB-300 in two different sites on tumours to assess tumour uptake, safety, pharmacodynamic activity and identify the recommended dose. METHODS Fourteen patients were treated with intralesional injections containing 35 or 70 mg of CIGB-300 in three alternate cycles of three consecutive days each before standard chemoradiotherapy. Tumour uptake was determined using (99)Tc-radiolabelled peptide. In situ B23/nucleophosmin was determined by immunohistochemistry. RESULTS Maximum tumour uptake for CIGB-300 70-mg dose was significantly higher than the one observed for 35 mg: 16.1 ± 8.9 vs 31.3 ± 12.9 mg (P = 0.01). Both, AUC24h and biological half-life were also significantly higher using 70 mg of CIGB-300 (P < 0.001). Unincorporated CIGB-300 diffused rapidly to blood and was mainly distributed towards kidneys, and marginally in liver, lungs, heart and spleen. There was no DLT and moderate allergic-like reactions were the most common systemic side effect with strong correlation between unincorporated CIGB-300 and histamine levels in blood. CIGB-300, 70 mg, downregulated B23/nucleophosmin (P = 0.03) in tumour specimens. CONCLUSION Intralesional injections of 70 mg CIGB-300 in two sites (0.5 ml per injection) and this treatment plan are recommended to be evaluated in phase 2 studies.
Collapse
Affiliation(s)
- M R Sarduy
- Gynecological service, Center for Medical-Surgical Research, Havana 11300, Cuba
| | - I García
- CIGB-300 Research and Development Group, Laboratory of Molecular Oncology, Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), Avenue 31 b/158 and 190, Cubanacán, Playa, PO Box 6162, Havana 11300, Cuba
| | - M A Coca
- Direction for Clinical Research, Clinical Investigation Center, Havana 11300, Cuba
| | - A Perera
- Direction for Clinical Research, Clinical Investigation Center, Havana 11300, Cuba
| | - L A Torres
- Direction for Clinical Research, Clinical Investigation Center, Havana 11300, Cuba
| | - C M Valenzuela
- CIGB-300 Research and Development Group, Laboratory of Molecular Oncology, Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), Avenue 31 b/158 and 190, Cubanacán, Playa, PO Box 6162, Havana 11300, Cuba
| | - I Baladrón
- CIGB-300 Research and Development Group, Laboratory of Molecular Oncology, Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), Avenue 31 b/158 and 190, Cubanacán, Playa, PO Box 6162, Havana 11300, Cuba
| | - M Solares
- Gyneco-obstetric Hospital ‘Ramón González Coro', Havana 10400, Cuba
| | - V Reyes
- CIGB-300 Research and Development Group, Laboratory of Molecular Oncology, Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), Avenue 31 b/158 and 190, Cubanacán, Playa, PO Box 6162, Havana 11300, Cuba
| | - I Hernández
- Deparment of Development, Isotope Center (CENTIS), Havana 11100, Cuba
| | - Y Perera
- CIGB-300 Research and Development Group, Laboratory of Molecular Oncology, Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), Avenue 31 b/158 and 190, Cubanacán, Playa, PO Box 6162, Havana 11300, Cuba
| | - Y M Martínez
- Gynecological service, Center for Medical-Surgical Research, Havana 11300, Cuba
| | - L Molina
- Gynecological service, Center for Medical-Surgical Research, Havana 11300, Cuba
| | - Y M González
- Gynecological service, Center for Medical-Surgical Research, Havana 11300, Cuba
| | - J A Ancízar
- CIGB-300 Research and Development Group, Laboratory of Molecular Oncology, Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), Avenue 31 b/158 and 190, Cubanacán, Playa, PO Box 6162, Havana 11300, Cuba
| | - A Prats
- Direction for Clinical Research, Clinical Investigation Center, Havana 11300, Cuba
| | - L González
- CIGB-300 Research and Development Group, Laboratory of Molecular Oncology, Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), Avenue 31 b/158 and 190, Cubanacán, Playa, PO Box 6162, Havana 11300, Cuba
| | - C A Casacó
- Direction for Clinical Research, Clinical Investigation Center, Havana 11300, Cuba
| | - B E Acevedo
- CIGB-300 Research and Development Group, Laboratory of Molecular Oncology, Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), Avenue 31 b/158 and 190, Cubanacán, Playa, PO Box 6162, Havana 11300, Cuba
| | - P A López-Saura
- CIGB-300 Research and Development Group, Laboratory of Molecular Oncology, Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), Avenue 31 b/158 and 190, Cubanacán, Playa, PO Box 6162, Havana 11300, Cuba
| | - D F Alonso
- Molecular Oncology Laboratory, National University of Quilmes, Buenos Aires, Argentina
| | - R Gómez
- ELEA Laboratories, Buenos Aires, Argentina
| | - S E Perea-Rodríguez
- CIGB-300 Research and Development Group, Laboratory of Molecular Oncology, Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), Avenue 31 b/158 and 190, Cubanacán, Playa, PO Box 6162, Havana 11300, Cuba
| |
Collapse
|